I bet that was why they didn't mention the booking number in the CC, and quite lamely use some bogus confidentiality excuse to hide the number. Stock price will test recent low of 5 dollars.
Which Genomic company did really shine so far? Millenium did not have a product until they bought Velcade rights...developed by another company. Tell me how do you design a drug based on a single mutation or multiple mutations. Answer me if you care. I bet, you are not familiar with science. Yes, sequencing can detect somatic mutations in certain tissue DNAs but then what?
There you have it, ladies and gentleman. Genomics is a bust. Just another friendly hint from madmonsoon2000.
Personalized medicine is a total BS. Most of the genomic DNA is just junk. If you find a mutation in the introns, that may not give you any clue, let alone a personalized medicine. Moreover, most the diseases are multi-factoral or environmental. Personalized medicine would not be much help. It is rather a sexy word for grant money.
Of course it should work. But that is not the question. Can it survive the ruthless competition from the Goliath? It will see meet a slow death. Mark my word!
I was there on the message board when Helicos was trading around 4-5 dollars. I was blunt and not many people listened. I heard about the uniqueness of that company becoming another giant in diagnostic sequencing. And now, we know the story. PACB machines are expensive compared to ILMN. I addition PACB is not selling that many machines in comparison to Illumina. Most of the companies/universities have gone with Illumina.
Yes, the death will be slow. I would touch this company. Take a chance with an oil drillers like RIG. That would be far more rewarding in long run. Thank you.
Pacbio will continue to increase in value due to increased sales and consumable income, not to mention all the companies adopting their superiour real time sequencing technology. It will excel when new sequencer is released
PACB, Q1, Operating Metrics Released
— 7:56 PM ET 05/05/2015
Revenue : Contractual revenue
--- Actual: 3.6, Est: 1.7, Surprise (vs. consensus): 111.53%
Revenue : Product revenue
--- Actual: 11.3, Est: 10.0, Surprise (vs. consensus): 12.74%
Revenue : Service and other revenue
--- Actual: 2.7, Est: 2.4, Surprise (vs. consensus): 13.73%
In the beginning of adoption of this technology!!!!
Expect a short squeeeeeeeze tomorrow morning! 8.51 M shorts. That is very significant. Will we reach the 52-week high again? $8.78 won't be too far away.
Nice done, PACB. And, congratulations, longs!
Sentiment: Strong Buy
This is a huge success for Pac Bio. Just need to get their sequencing rxn costs down. Well done Pac Bio!!!
PacBio RS II Systems to Be Used for Projects Such As De Novo Genome Assembly, Whole-Genome Methylation Analysis and Transcript Isoform Characterization
"The de novo genome services offered by BGI will be supported by SMRT sequencing technology to take advantage of its long reads and improved accuracy of assembly," said Dr. Wang Jun, CEO of BGI. "The PacBio platform is ideal for complex genomes, such as those that are highly repetitive or hybrid. With the PacBio RS II we expect to meet our goal of delivering only complete genomes to our customers, and providing the best possible reference genomes for plants, animals and humans."
Michael Hunkapiller, President and CEO of Pacific Biosciences, commented, "It's a great validation to us that the world's leading and largest sequencing operation has adopted PacBio technology. BGI is also a leader in sequencing data analysis, so we are delighted that more SMRT Sequencing data will be in their hands to work with and hopefully develop additional tools to help realize the full value of the data."